NCT02647632View on ClinicalTrials.gov

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

April 30, 2017

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir/Elbasvir

DRUG

Sofosbuvir

DRUG

Ribavirin

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT02647632 - Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir | Biotech Hunter | Biotech Hunter